Day: August 9, 2021

Conference Call on Monday, August 9, 2021, at 4pm ET RESTON, Va., Aug. 09, 2021 (GLOBE NEWSWIRE) — Lightbridge Corporation (NASDAQ: LTBR), an advanced nuclear fuel technology company, announced financial results for the second quarter ended June 30, 2021, and provided an update on the Company’s continued progress. Seth Grae, President & Chief Executive Officer of Lightbridge Corporation, commented, “We are pleased with the strong progress of our fuel development activities thus far in 2021, including the successful demonstration of our proprietary coextrusion manufacturing process. We produced rods of a length designed for small modular reactors, using nuclear-grade zirconium alloy cladding material and a displacer produced from nuclear-grade zirconium, and surrogate materials that mimic the relevant properties of uranium.” “Lightbridge...

Highest on-time performance of all airlines from Keflavik Iceland in July   Load factor was 41.7%   New pandemic restrictions negatively impacted travel trend in July July was the first operational month for PLAY and, as such, was a success.  PLAY’s main objective was to begin operation in a safe and trustworthy manner while focusing on the satisfaction of passengers. A key indicator of that success is the fact that PLAY had the highest on-time performance of all airlines operating to and from Keflavik Iceland in July, with 96.2% of all PLAY flights arriving on schedule.     PLAY received three A321 neo aircraft this summer following a very efficient and professional effort from its technical and operations teams. These aircraft will come into operation in line with the market demand while utilizing very favorable leasing terms that...

Company Ended the Quarter With Cash of Approximately $379 Million and Subsequently Received a Direct Investment of $200 Million from Roivant NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal first quarter ended June 30, 2021. Immunovant ended the quarter with approximately $379 million in cash. “We are excited to announce that in July 2021, the FDA granted Orphan Drug Designation to IMVT-1401 for treatment of Myasthenia Gravis,” said Pete Salzmann, M.D., Chief Executive Officer of Immunovant. “We have also initiated engagement with the FDA’s Division of Neurology to discuss protocol modifications for a pivotal study in Myasthenia Gravis and our...

Coinstar to join Lottery.com’s Affiliate Program AUSTIN, Texas and BELLEVUE, Wash., Aug. 09, 2021 (GLOBE NEWSWIRE) — AutoLotto, Inc. (“Lottery.com”), a leading technology company that is transforming how, where and when the lottery is played, today announced that Coinstar, LLC (“Coinstar”®), a global leader in self-service coin counting, is joining Lottery.com’s affiliate program.  Through its agreement with Lottery.com, Coinstar will market and promote Lottery.com products in California, Texas, Pennsylvania, Michigan and other U.S. jurisdictions where Lottery.com currently offers its services by utilizing its network of 4,450 interactive kiosks in these areas, including ones equipped with adPlanet™ lead generation technology. The addition of Coinstar will expand Lottery.com’s existing affiliate program, which includes leading...

BENTONVILLE, AR, Aug. 09, 2021 (GLOBE NEWSWIRE) — Glucose Health, Inc. (OTC Pink: GLUC) (“Company”) is pleased to highlight key financial information detailed in its June 30, 2021 Quarterly Report, posted this morning at OTCMarkets.com.YTD Fiscal 2021 Revenue of $524,568 vs. $234,752 for YTD Fiscal 2020 – an increase of 123% Q2 Fiscal 2021 Revenue of $287,103 vs. $151,139 for Q2 Fiscal 2020 – an increase of 89% YTD Fiscal 2021 Gross Profit of $217,794 vs. $96,886 for YTD Fiscal 2020 – an increase of 125% Q2 Fiscal 2021 Gross Profit of $102,923 vs. $69,906 for YTD Fiscal 2020 – an increase of 47%GLUCODOWN® sales at Amazon for April 2021, the first month of Q2, reached a new monthly record of $74,944, beating the previous monthly sales record of $38,595 announced by the Company for June 2020, by 94%. Important:  Additional...

HighlightsSecond quarter revenue of $1,282.6 million, increased 6.1% sequentially and 26.6% year-over-year. Clinical Solutions net new business awards of $1,436.2 million for the second quarter, representing year-over-year growth of 21.2% and a book-to-bill ratio of 1.45x, and $4,971.5 million for the trailing twelve months, representing year-over-year growth of 8.2% and a book-to-bill ratio of 1.37x. Commercial Solutions net new business awards of $273.6 million for the second quarter, representing year-over-year growth of 55.3% and a book-to-bill ratio of 0.94x, and $1,257.4 million for the trailing twelve months, representing year-over-year growth of 4.8% and a book-to-bill ratio of 1.14x. Year-over-year ending backlog growth of 21.5% in Clinical Solutions and 17.8% in Deployment Solutions as of June 30, 2021. GAAP net income of $41.9...